TRPM8 and prostate carcinoma: For instance, transient receptor potential cation channel subfamily M member 8 (TRPM8) was proved to serve as a crucial role in advanced stage III/IV prostate cancers, and the TRPM8-induced calcium cytotoxicity could sensitize tumor cells to standard-of-care treatment, which provided additional clinical benefits [44].